Arcus Biosciences, Inc. (RCUS)
23.01
+0.62
(+2.77%)
USD |
NYSE |
Apr 14, 16:00
23.01
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Cash from Investing (TTM) : 66.00M for Dec. 31, 2025
Cash from Investing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (TTM) Benchmarks
| Gilead Sciences, Inc. | -4.793B |
| ACADIA Pharmaceuticals, Inc. | -302.56M |
| Alnylam Pharmaceuticals, Inc. | 436.33M |
| Regeneron Pharmaceuticals, Inc. | -629.10M |
| Sarepta Therapeutics, Inc. | 69.64M |